Inve US ▾

Corcept Therapeutics (CORT) earnings

CORCEPT THERAPEUTICS INC· Health Care

Results to
Jun 2026
Latest analysed call
Jun 2026 (Q2 FY26)
Balance sheet to
Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Corcept Therapeutics earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue256 $ million+31.7% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin16.1 %+2.4 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit43.0 $ million+22.3% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Guidance

What management said, and what became of it

17 of 21 judged targets kept · 16 open · verdicts reflect calls analysed to Jun 2026.

CORCEPT THERAPEUTICS INC management guidance track record: 37 targets tracked across analysed earnings calls (17 achieved, 4 missed, 16 open).

TargetOriginal wordingSaidLatest callVerdict
Dazucorilant Phase III ALS trial startStart the Phase III ALS trial by the middle of 2026Sep 2025Jun 2026:The findings from this study will inform the design of the pivotal trial that we plan to start early next year.
Call transcript, Jun 2026 · no direct link		Delayed
Annual revenue of the current Cushing's syndrome business with existing medicationsAt least $2 billion in annual revenue by the end of the decadeDec 2025Jun 2026:propelling our current Cushing's syndrome business to at least $2 billion in annual revenue by the end of this decade
Call transcript, Jun 2026 · no direct link		On Track
Meeting with the FDA on the relacorilant complete response letterMeet with the FDA in April 2026Dec 2025Mar 2026:In April, we met with the FDA regarding relacorilant's new drug application, its NDA in Cushing's syndrome.
Call transcript, Mar 2026 · no direct link		Achieved

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of CORCEPT THERAPEUTICS INC's 37 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 34 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. US Pro opens 100 a month: first month free, no card.
See the full record

Price

$112.1 +1.76% · +$1.94

Last close Oct 19, 2026 · US · USD

Performance +42.5% 1Y

$40$60$80$100$120Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Aug 26Oct 26Dec 2025 (Q4 FY25) — 24 Feb 2026Mar 2026 (Q1 FY26) — 30 Apr 2026Jun 2026 (Q2 FY26) — 29 Jul 2026

1Y: $78.69 on 17 Oct 2025 → $112.1. High $123.57 (25 Aug 2026), low $32.15 (13 Mar 2026).

Previous close
$110.16
52-week range
$32.15 – $123.57
One year
+42.62%

Overview

Symbol
CORT
Exchange
US
Currency
USD

Your own record

Start an Inve Case for CORCEPT THERAPEUTICS INC

Free account. Everything above stays public.

Write why you follow CORCEPT THERAPEUTICS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other US companies filed under C

All 315 companies under C

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered